| Literature DB >> 35544247 |
Yana Ilyina1, Eugenia Fot1, Vsevolod Kuzkov1, Mikhail Kirov1.
Abstract
OBJECTIVE: Sepsis-associated endothelial dysfunction and degradation result in release of inflammatory mediators, compromise endothelial permeability, and impair alveolar fluid clearance leading to pulmonary edema. Excessive fluid therapy in septic shock damage the endothelial glycocalyx which will increase capillary leakage. The aim of our study was to assess the relationship of endothelial glycocalyx shedding with hemodynamic and metabolic response to fluid load in patients with septic shock.Entities:
Year: 2022 PMID: 35544247 PMCID: PMC9361336 DOI: 10.5152/TJAR.2021.21224
Source DB: PubMed Journal: Turk J Anaesthesiol Reanim ISSN: 2149-276X
The Clinical Characteristics of the Patients
| Parameter | Value |
|---|---|
| Age (years) | 55 ± 16 |
| Gender (male/female) | 11/7 |
| Fluid responders/nonresponders | 10/8 |
| Fluid balance in 24 hours (mL) | 3560 ± 1870 |
| SOFA (baseline) | 11 (8-12) |
| SOFA (24 hours) | 9 (7-10) |
| Dose of epinephrine (μg kg min) | 0.37 (0.20-0.50) |
| Dose of norepinephrine (μg kg min) | 0.88 (0.60-1.49) |
| Diagnosis, n (%) | |
| Pneumonia | 6 (33) |
| Necrotizing pancreatitis | 5 (28) |
| Peritonitis | 6 (33) |
| Liver abscess | 1 (6) |
| Duration of ICU stay (days) | 10 (6-26) |
| Duration of hospital stay (days) | 17 (7-32) |
| Mortality at day 28, n (%) | 8 (44) |
ICU, intensive care unit.
The Changes of Study Parameters
| Parameter | Stage | ||
|---|---|---|---|
| Baseline | 2 hours After FLT | 24 hour After FLT | |
| MAP (mm Hg) | 81 (65-97) | 79 (63-95) | 81 (61-101) |
| CI (L min−1 m−2) | 3.23 (2.64-4.29) | 2.95 (2.63-3.90) | 3.79 (3.21-5.22)* |
| SVRI (dyn × s cm−5 m−2) | 1853 (1130-2576) | 1770 (1178-2362) | 1597(624-2570) |
| GEDVI (mL m−2) | 654 (595-808) | 674 (614-743) | 724 (559-852) |
| PPV (%) | 16 (9-23) | 13 (6-20) | 15 (8-22) |
| SVV (%) | 22 (14-30) | 15 (9-21) | 14 (8-20) |
| EVLWI (mL kg−1) | 7 (5-21) | 8 (6-16) | 9 (6-23) |
| PVPI | 4.2 (3.1-6.4) | 4.5 (3.2-6.5) | 5.5 (3.3-6.9)* |
| PaO2/FiO2 (mm Hg) | 228 (177-310) | 219 (172-254) | 258 (141-348) |
| Glucose (mmol L−1) | 13.1 (9.2-16.7) | 13.1 (8.9-17.0) | 9.1 (7.7-10.9) |
| Lactate (mmol L−1) | 4.5 (2.7-6.7) | 3.7 (2.2-5.8) | 2.0 (1.5-4.1) |
| HSPG (ng mL−1) | 2.73 (1.7-7.28) | 3.26 (1.87-5.83) | 1.70 (1.36-5.58) |
| S1 (ng mL−1) | 1.08 (0.80-2.64) | 1.49 (0.87-4.45) | 0.93 (0.47-2.27) |
* P < .05 compared with baseline, Wilcoxon test. CI, cardiac index; EVLWI, extravascular lung water index; GEDVI, global end-diastolic volume index; HSPG, heparan sulfate proteoglycan; MAP, mean arterial pressure; PPV, pulse pressure variation; PVPI, pulmonary vascular permeability index; S1, syndecan 1; SVV, stroke volume variation; SVRI, systemic vascular resistance index.
The Changes of Study Parameters in Groups of Responders and Nonresponders to Fluid Load
| Parameter | Responders (n = 10) | Nonresponders (n = 8) | ||||
|---|---|---|---|---|---|---|
| Baseline | 2 hours After FLT | 24 hours After FLT | Baseline | 2 hours After FLT | 24 hours After FLT | |
| MAP (mm Hg) | 84 (74-89) | 78 (58-95) | 97 (66-108) | 85 (81-88) | 84 (76-86) | 74 (68-78)* |
| HR (bpm) | 116 (103-128) | 100 (88-115)* | 109 (83-113) | 127 (97-135) | 111 (90-124) | 104 (97-120) |
| CI (L min−1 m−2) | 2.9 (2.1-3.9) | 2.9 (3.4-3.7) | 3.4 (2.3-5.3) | 3.2 (3.2-6.0) | 3.1 (2.6-4.3) | 4.0 (3.2-5.3)* |
| SVRI (dyn × s cm−5 m−2) | 1855 (1134-3045) | 1586 (1302-2247) | 1272 (1188-2577) | 1446 (961-1942) | 1775 (1217-2194) | 1081 (731-1661)* |
| GEDVI (mL m−2) | 642 (580-687) | 668 (604-706)* | 675 (534-892) | 771 (636-840) | 717 (640-764) | 713 (519-833) |
| PPV (%) | 19 (9-20) | 12 (7-21) | 17 (8-22) | 16 (12-19) | 8 (7-16)* | 14 (12-16) |
| SVV (%) | 24 (9-28) | 14 (10-17) | 15 (9-23) | 25 (17-32) | 13 (7-18) | 12 (9-16) |
| EVLWI (mL kg−1) | 8 (6-11) | 9 (6-12) | 10 (7-13)* | 15 (7-16) | 9 (7-12) | 8 (6-11) |
| Lactate (mmol L−1) | 2.8 (2.1-7.1) | 2.4 (2.2-6.8) | 2.6 (1.3-4.1) | 4.5 (3.6-6.6) | 4.7 (4.7-5.3) | 1.9 (1.6-5.5) |
| Dose of norepinephrine (mcg kg min) | 0.73 (0.60-1.47) | 0.50 (0.24-0.90) | 0.05 (0.01-0.72)* | 0.82 (0.21-1.05) | 0.57 (0.10-1.0) | 0.08 (0.02-0.43) |
| Duration of ICU stay (days) | 9 (6-24) | 10 (8-26) | ||||
| Duration of hospital stay (days) | 16 (8-32) | 15 (7-26) | ||||
| Mortality at day 28 (n [%]) | 3 (33%) | 5 (63%) | ||||
* P < .05 compared with baseline, Wilcoxon test. CI, cardiac index; EVLWI, extravascular lung water index; GEDVI, global end-diastolic volume index; HR, heart rate; MAP, mean arterial pressure; PPV, pulse pressure variation; SVV, stroke volume variation; SVRI, systemic vascular resistance index.
Figure 1.The relationship of glycocalix with severity of pulmonary edema during the study. (A) Correlation of extravascular lung water index (EVLWI) with syndecan 1 concentration at baseline. (B) Correlation of EVLWI with heparan sulfate proteoglycan at 24 hrs after fluid load.
Figure 2.Correlation of lactate concentration with syndecan 1 during the study. (A) Correlation of lactate with syndecan 1 concentration at baseline. (B) Correlation of lactate with syndecan 1 concentration at 24 hrs after fluid load.